SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation

Journal of Immunology

Volumn 183, Issue 4, 2009, Pages 2775-2784

  Luciani, Alessandro ^a,b   Villella, Valeria Rachela ^c   Vasaturo, Angela ^c   Giardino, Ida ^a   Raia, Valeria ^c   Pettoello Mantovani, Massimo ^a   D'Apolito, Maria ^a   Guido, Stefano ^b,c   Leal, Teresinha ^d   Quaratino, Sonia ^e   Maiuri, Luigi ^a,f  

^a UNIVERSITY OF FOGGIA   (Italy)

^b Centro di Ingegneria Genetica   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEASOME; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN INHIBITOR OF ACTIVATED STAT; SUMO 1 PROTEIN; SUPEROXIDE DISMUTASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; PIAS4 PROTEIN, HUMAN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; SUMO1 PROTEIN, HUMAN; TISSUE TRANSGLUTAMINASE 2, HUMAN;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; CYSTIC FIBROSIS; ENZYME ACTIVATION; ENZYME DEGRADATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; NOSE POLYP; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SUMOYLATION; UBIQUITINATION; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MICE; MICE, MUTANT STRAINS; OXIDATIVE STRESS; PROTEIN INHIBITORS OF ACTIVATED STAT; REACTIVE OXYGEN SPECIES; RESPIRATORY MUCOSA; SUMO-1 PROTEIN; TRANSGLUTAMINASES;

EID: 70149091116     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900993     Document Type: Article

References (49)

1. Ratjen, F., and G. Doring. 2003. Cystic fibrosis. Lancet 361: 681-689.
2. Thelin, W. R., Y. Chen, M. Gentzsch, S. M. Kreda, J. L. Sallee, C. O. Scarlett, C. H. Borchers, K. Jacobson, M. J. Stutts, and S. L. Milgram. 2007. Direct interaction with filamins modulates the stability and plasma membrane expression of CFTR. J. Clin. Invest. 117: 364-374.
3. Gelman, M. S., and R. R. Kopito. 2003. Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism. Methods Mol. Biol. 232: 27-37.
4. Kopito, R. R. 1999. Biosynthesis and degradation of CFTR. Physiol. Rev. 79: S167-S173.
5. Reddy, M. M., P. M. Quinton, C. Haws, J. J. Wine, R. Grygorczyk, J. A. Tabcharani, J. W. Hanrahan, K. L. Gunderson, and R. R. Kopito. 1996. Failure of the cystic fibrosis transmembrane conductance regulator to conduct ATP. Science 271: 1876-1879.
6. Ward, C. L., S. Omura, and R. R. Kopito. 1995. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83: 121-127.
7. Proesmans, M., F. Vermeulen, and K. De Boeck. 2008. What's new in cystic fibrosis?: from treating symptoms to correction of the basic defect. Eur. J. Pediatr. 167: 839-849.
8. Verkman, A. S., and L. J. Galietta. 2009. Chloride channels as drug targets. Nat. Rev. Drug Discov. 8: 153-171.
9. Caputo, A., E. Caci, L. Ferrera, N. Pedemonte, C. Barsanti, E. Sondo, U. Pfeffer, R. Ravazzolo, O. Zegarra-Moran, and L. J. Galietta. 2008. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322: 590-594.
10. Scheid, P., L. Kempster, U. Griesenbach, J. C. Davies, A. Dewar, P. P. Weber, W. H. Colledge, M. J. Evans, D. M. Geddes, and E. W. Alton. 2001. Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence. Eur. Respir. J. 17: 27-35.
11. Smith, J. J., S. M. Travis, E. P. Greenberg, and M. J. Welsh. 1996. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85: 229-236.
12. Kowalski, M. P., A. Dubouix-Bourandy, M. Bajmoczi, D. E. Golan, T. Zaidi, Y. S. Coutinho-Sledge, M. P. Gygi, S. P. Gygi, E. A. Wiemer, and G. B. Pier. 2007. Host resistance to lung infection mediated by major vault protein in epithelial cells. Science 6: 130-132.
13. Thelin, W. R., and R. C. Boucher. 2007. The epithelium as a target for therapy in cystic fibrosis. Curr. Opin. Pharmacol. 7: 290-295.
14. Escotte, S., O. Tabary, D. Dusser, C. Majer-Teboul, E. Puchelle, and J. Jacquot. 2003. Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-β kinase pathway. Eur. Respir. J. 21: 574-581. (Pubitemid 36432507)
15. Rottner, M., C. Kunzelmann, M. Mergey, J. M. Freyssinet, and M. C. Martinez. 2007. Exaggerated apoptosis and NF-κB activation in pancreatic and tracheal cystic fibrosis cells. FASEB J. 21: 2939-2948.
16. Venkatakrishnan, A., A. A. Stecenko, G. King, T. R. Blackwell, K. Brigham, J. W. Christman, and T. S. Blackwell. 2000. Exaggerated activation of nuclear factor-κB and altered IκB-beta processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 23: 396-403.
17. Becker, M. N., M. S. Sauer, M. S. Muhlebach, A. J. Hirsh, Q. Wu, M. W. Verghese, and S. H. Randell. 2004. Cytokine secretion by cystic fibrosis airway epithelial cells. Am. J. Respir. Crit. Care Med. 169: 645-653.
18. 2+ of airway epithelia. Am. J. Physiol. 293: L1250-L1260.
19. Teichgräber, V., M. Ulrich, N. Endlich, J. Riethmüller, B. Wilker, C. C. De Oliveira-Munding, A. M. van Heeckeren, M. L. Barr, G. von Kürthy, K. W. Schmid, et al. 2008. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 14: 382-391.
20. Perez, A., A. C. Issler, C. U. Cotton, T. J. Kelley, A. S. Verkman, and P. B. Davis. 2007. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am. J. Physiol. 292: L383-L395.
21. Verhaeghe, C., C. Remouchamps, B. Hennuy, A. Vanderplasschen, A. Chariot, S. Tabruyn, C. Oury, and V. Bours. 2007. Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem. Pharmacol. 73: 1982-1994.
22. Maiuri, L., A. Luciani, I. Giardino, V. Raia, V. R. Villella, M. D'Apolito, M. Pettoello-Mantovani, S. Guido, C. Ciacci, M. Cimmino, et al. 2008. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARγ down-regulation. J. Immunol. 180: 7697-7705.
23. Rottner, M., J. M. Freyssinet, and M. C. Martínez. 2009. Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir. Res. 10: 23.
24. Vij, N., S. Mazur, and P. L. Zeitlin. 2009. CFTR is a negative regulator of NFκB mediated innate immune response. PLoS ONE 4: e4664.
25. Lorand, L., and R. M. Graham. 2003. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4: 140-156.
26. Daynes, R. A., and D. C. Jones. 2002. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2: 748-759.
27. Malorni, W., M. G. Farrace, C. Rodolfo, and M. Piacentini. 2008. Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection. Curr. Pharm. Des. 14: 278-288.
28. Lorand, L. 1996. Neurodegenerative diseases and transglutaminase. Proc. Natl. Acad. Sci. USA 93: 14310-14313.
29. Molberg, O., S. N. Mcadam, R. Körner, H. Quarsten, C. Kristiansen, L. Madsen, L. Fugger, H. Scott, O. Norén, P. Roepstorff, et al. 1998. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4: 713-717.
30. Verna, A., H. Wang, B. Manavathi, J. Y. Fok, A. P. Mann, R. Kumar, and K. Mehta. 2006. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 66: 10525-10533.
31. Meulmeester, E., and F. Melchior. 2008. Cell biology: SUMO. Nature 452: 709-711.
32. Geiss-Friedlander, R., and F. Melchior. 2007. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8: 947-956.
33. Mabb, A. M., and S. M. Wuerzberger-Davis. 2006. PIASy mediates NEMO sumoylation and NF-κB activation in response to genotoxic stress. Nat. Cell Biol. 8: 986-993.
34. Carbia-Nagashima, A., J. Gerez, C. Perez-Castro, M. Paez-Pereda, S. Silberstein, G. K. Stalla, F. Holsboer, and E. Arzt. 2007. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1α during hypoxia. Cell 131: 309-323.
35. Du, X., D. Edelstein, S. Obici, N. Higham, M. H. Zou, and M. Brownlee. 2006. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J. Clin. Invest. 116: 1071-1079.
36. Legssyer, R., F. Huaux, J. Lebacq, M. Delos, E. Marbaix, P. Lebecque, D. Lison, B. J. Scholte, P. Wallemacq, and T. Leal. 2006. Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice. Respir. Res. 7: 134.
37. Nicklas, W., P. Baneux, R. Boot, T. Decelle, A. A. Deeny, M. Fumanelli, and B. Illgen-Wilcke; for FELASA (Federation of European Laboratory Animal Science Associations Working Group on Health Monitoring of Rodent and Rabbit Colonies). 2002. Recommendation for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab. Anim. 36: 20-42.
38. Karpuj, M. V., M. W. Becher, J. E. Springer, D. Chabas, S. Youssef, R. Pedotti, D. Mitchell, and L. Steinman. 2002. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8: 143-149.
39. Kenworthy, A. K. 2001. Imaging protein-protein interactions using fluorescence resonance energy transfer microscopy. Methods 24: 289-296.
40. Müller, S., and C. Hoege. 2001. SUMO-1, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2: 202-210.
41. Raia, V., L. Maiuri, C. Ciacci, I. Ricciardelli, L. Vacca, S. Auricchio, M. Cimmino, M. Cavaliere, M. Nardone, A. Cesaro, et al. 2005. Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis. Thorax 60: 773-780.
42. Martinvalet, D., D. M. Dykxhoorn, R. Ferrini, and J. Lieberman. 2008. Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell 133: 681-692.
43. Muniyappa, H. B., S. Song, C. K. Mathews, and K. C. Das. 2009. Reactive oxygen species-independent oxidation of thioredoxin in hypoxia: inactivation of ribonucleotide reductase and redox-mediated checkpoint control. J. Biol. Chem. 284: 17069-17081.
44. Pascual, G., A. L. Fong, S. Ogawa, A. Gamliel, A. C. Li, V. Perissi, D. W. Rose, T. M. Willson, M. G. Rosenfeld, and C. K. Glass. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437: 759-763.
45. Kim, D. S., S. S. Park, B. H. Nam, I. H. Kim, and S. Y. Kim. 2006. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-κB inactivation. Cancer Res. 66: 10936-10943.
46. Tempè, D., M. Piechaczyk, and G. Bossis. 2008. SUMO under stress. Biochem. Soc. Trans. 36: 874-878.
47. Quintanilla, R. A., Y. N. Jin, K. Fuenzalida, M. Bronfman, and G. V. Johnson. 2008. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-γ (PPARγ) in the pathogenesis of Huntington disease. J. Biol. Chem. 283: 25628-25637.
48. Steffan, J. S., N. Agrawal, J. Pallos, E. Rockabrand, L. C. Trotman, N. Slepko, K. Illes, T. Lukacsovich, Y. Z. Zhu, E. Cattaneo, et al. 2004. SUMO modification of huntingtin and Huntington's disease pathology. Science 304: 100-104.
49. Juun, E., R. D. Ronchetti, M. M. Quezado, S. Y. Kim, and M. M. Mouradian. 2003. Tissue transglutaminase-induced aggregation of α-synuclein: implication for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 100: 2047-2052.